每日补锌预防镰状细胞贫血患儿感染:ZIPS-2随机临床试验
在乌干达Jinja地区开展的双盲安慰剂对照试验纳入100名1.00至4.99岁镰状细胞贫血患儿,随机接受每日20 mg硫酸锌或安慰剂治疗6个月。锌组全因感染率为305.7/100人年,显著低于安慰剂组的480.7/100人年,校正后发生率比为0.62,未观察到需停药的 adverse events。
要点
- 每日20 mg锌可降低5岁以下镰状细胞贫血患儿全因感染率。
- 锌组感染率为305.7/100人年,安慰剂组为480.7/100人年。
- 两组均未出现需停用研究干预的 adverse events。
核心结论
- 每日20 mg锌补充可降低乌干达5岁以下镰状细胞贫血患儿的全因感染。
- 校正基线年龄、性别和羟基脲使用后,感染发生率比为0.62(95%CI 0.45-0.86)。
研究设计与样本
- 随机、双盲、安慰剂对照试验,在乌干达Jinja地区Jinja Regional Referral Hospital开展。
- 纳入100名1.00至4.99岁镰状细胞贫血患儿,随机分为锌组(n=50)和安慰剂组(n=50),随访6个月。
- 筛查118名儿童,100名随机分组;平均(SD)年龄36.0(13.2)个月,45名女性(45%)。
主要发现
- 锌组发生80例全因感染,安慰剂组发生124例。
- 锌组感染率305.7/100人年(95%CI 242.4-380.4),安慰剂组480.7/100人年(95%CI 399.8-573.1)。
- 率差为-176.0/100人年(95%CI -300.8至-51.3)。
- 随访期间所有参与者均完成 ascertainment,无失访。
- 两组均未观察到需停用研究干预的 adverse events。
关键数值与推荐
- 干预为每日20 mg硫酸锌或每日安慰剂,持续6个月。
- 主要结局为每100人年全因感染率,采用标准化临床标准定义感染。
- 入组时45名参与者(45%)正在接受羟基脲治疗,所有参与者在入组后开始或继续接受羟基脲。
临床怎么用
- 对于5岁以下镰状细胞贫血患儿,可考虑每日20 mg锌补充以降低全因感染风险。
- 试验中所有参与者均开始或继续羟基脲治疗,锌补充可作为现有预防策略的补充。
- 需多中心临床试验验证研究结果并评估对年长儿童的效果。
局限性
- 研究仅在乌干达Jinja单一中心开展,样本量100例,随访6个月。
- 研究对象为1.00至4.99岁儿童,结论不能直接外推至年长儿童或其他地区。
- 需多中心临床试验验证研究结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Despite existing prevention strategies, infections remain a major cause of morbidity and mortality in children in Africa with sickle cell anemia. OBJECTIVE: To determine the safety and effectiveness of daily zinc supplementation to prevent all-cause infection in children with sickle cell anemia in Uganda. DESIGN, SETTING, AND PARTICIPANTS: A randomized, double-blind, placebo-controlled trial of children aged 1.00 to 4.99 years with sickle cell anemia at Jinja Regional Referral Hospital in Jinja, Uganda, from February 10, 2025, to April 30, 2025, with 6 months of follow-up through November 7, 2025. INTERVENTIONS: Participants received zinc sulfate at 20 mg daily or placebo daily for 6 months. MAIN OUTCOMES AND MEASURES: The primary outcome was all-cause infections per 100 person-years, using standardized clinical criteria to define infections. RESULTS: Among 118 children screened for eligibility, 100 were randomly assigned to receive zinc supplementation (n = 50) or placebo (n = 50) (mean [SD] age, 36.0 [13.2] months; 45 female [45%]). At enrollment, 45 participants (45%) were receiving hydroxyurea therapy. All participants initiated or continued receiving hydroxyurea after enrollment. During the 6-month follow-up, there was complete ascertainment for all participants and no loss to follow-up. There were 80 all-cause infections in the zinc group and 124 in the placebo group, corresponding to a significantly lower infection rate in the zinc group than the placebo group (305.7 [95% CI, 242.4-380.4] infections per 100 person-years vs 480.7 [95% CI, 399.8-573.1] infections per 100 person-years; rate difference, -176.0 [95% CI, -300.8 to -51.3]; incidence rate ratio after adjustment for baseline age, sex, and hydroxyurea use, 0.62 [95% CI, 0.45-0.86]). No adverse events requiring discontinuation of the study intervention were observed in either group. CONCLUSIONS AND RELEVANCE: Zinc supplementation at 20 mg per day reduced all-cause infection in children with sickle cell anemia younger than 5 years in Uganda. Multisite clinical trials are needed to validate these findings and to assess effectiveness in older children. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06561061.
引用
- Namazzi R, Mellencamp KA, Bagala I, et al. Daily Zinc Supplementation for Infection Prevention in Children With Sickle Cell Anemia: The ZIPS-2 Randomized Clinical Trial. JAMA. 2026. PMID: 42616536. doi:10.1001/jama.2026.14190
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。